Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Am J Pathol. 2024 Apr;194(4):539-550. doi: 10.1016/j.ajpath.2023.06.017. Epub 2023 Jul 28.
This review focuses on technologies at the core of calcific aortic valve disease (CAVD) and drug target research advancement, including transcriptomics, proteomics, and molecular imaging. We examine how bulk RNA sequencing and single-cell RNA sequencing have engendered organismal genomes and transcriptomes, promoting the analysis of tissue gene expression profiles and cell subpopulations, respectively. We bring into focus how the field is also largely influenced by increasingly accessible proteome profiling techniques. In unison, global transcriptional and protein expression analyses allow for increased understanding of cellular behavior and pathogenic pathways under pathologic stimuli including stress, inflammation, low-density lipoprotein accumulation, increased calcium and phosphate levels, and vascular injury. We also look at how direct investigation of protein signatures paves the way for identification of targetable pathways for pharmacologic intervention. Here, we note that imaging techniques, once a clinical diagnostic tool for late-stage CAVD, have since been refined to address a clinical need to identify microcalcifications using positron emission tomography/computed tomography and even detect in vivo cellular events indicative of early stage CAVD and map the expression of identified proteins in animal models. Together, these techniques generate a holistic approach to CAVD investigation, with the potential to identify additional novel regulatory pathways.
这篇综述重点介绍了心脏瓣膜钙化疾病(CAVD)的核心技术和药物靶点研究进展,包括转录组学、蛋白质组学和分子影像学。我们研究了批量 RNA 测序和单细胞 RNA 测序如何分别产生生物体基因组和转录组,促进了组织基因表达谱和细胞亚群的分析。我们还关注了该领域如何受到越来越多的可及性蛋白质组分析技术的影响。总的来说,全局转录组和蛋白质组分析有助于增加对包括应激、炎症、低密度脂蛋白积累、钙和磷酸盐水平升高以及血管损伤等病理刺激下细胞行为和致病途径的理解。我们还探讨了直接研究蛋白质特征如何为药物干预的靶向途径识别铺平道路。在这里,我们注意到,影像学技术曾经是 CAVD 晚期的临床诊断工具,现已得到改进,以使用正电子发射断层扫描/计算机断层扫描来解决识别微钙化的临床需求,甚至可以检测到早期 CAVD 指示的体内细胞事件,并在动物模型中绘制鉴定蛋白质的表达图谱。这些技术共同为 CAVD 研究提供了一种整体方法,有可能发现更多新的调控途径。